In Vivo CAR-T细胞疗法开发解决方案

近年来,体内(In Vivo)CAR-T细胞疗法在癌症免疫治疗领域取得了革命性突破,与传统的体外(Ex Vivo)CAR-T疗法不同,In Vivo CAR-T技术通过递送载体将CAR编码基因直接导入患者体内的T细胞,实现免疫细胞的重编程。这一创新疗法不仅简化了治疗流程,还显著降低了生产成本,为癌症患者带来了更便捷、更高效的治疗选择。

体内CAR-T细胞疗法的主要优势

治疗时间短:利用现成的重编程载体使得体内CAR-T疗法比体外方法快几周。
治疗成本低:每剂成本预计低至5000美元,仅为当前传统CAR-T疗法成本的一部分。
改善患者预后:患者保留完整的免疫系统,无需接受高强度化疗,减少免疫细胞耗竭,提高抗癌效果。
Trends Pharmacol Sci. 2024;45(5):406-418.

Trends Pharmacol Sci. 2024;45(5):406-418.

早期研发
抗体筛选
CAR DNA或mRNA载体设计
递送系统设计
体外和体内疗效早期测试
毒性研究
CMC
质粒DNA生产
mRNA生产与纯化
Ab-LNPs的开发及表征
灌装与成品工艺
供应链和物流管理
毒性研究
临床
安全性与疗效评估
剂量确定
副作用监测
长期影响研究

体内CAR-T细胞疗法工作流程

递送载体表面抗体密度定量

在In Vivo CAR-T细胞疗法,递送载体的靶向性至关重要。为提升递送效率,通常会用脂质纳米颗粒(Lipid Nanoparticles,LNP)或慢病毒(Lentivirus,LV)等递送载体表面连接靶向抗体,形成抗体偶联递送载体,从而显著增强其对特定细胞(如T细胞、B细胞)的识别与定位能力,实现精准治疗。常见的靶向抗体包括CD3、CD4、CD5、CD7 、CD8等,这些抗体能够有效引导递送载体精准识别目标细胞。递送载体表面偶联抗体的密度和活性,是直接影响该疗法质量、安全性和疗效的关键指标。我们开发了一系列具有确定荧光/蛋白(F/P值)比率的高活性荧光标记蛋白,经严格验证,适用于递送载体表面抗体密度的可靠定量分析。

产品列表

In Vivo CAR-T
In Vivo HSC
In Vivo CAR-NK

产品优势

即用型设计,可提供多种浓度的流式细胞术验证数据
即用型设计,可提供多种浓度的流式细胞术验证数据

1e5 of Mouse Anti-CD7 antibody coupled beads (5.5 μm) were stained with different concentration of Alexa Fluor™ 647-Labeled Human CD7 Protein, His Tag (Cat. No. CD7-HA2H4) and negative control protein respectively, AF647 signal was used to evaluate the binding activity (QC tested).

下载Protocol

Ready-to-use due to validation data with various concentration by flow cytometry

1e5 of Mouse Anti-CD8 antibody coupled beads (5.5 μm) were stained with different concentration of Alexa Fluor™ 488-Labeled Human CD8 alpha Protein, His Tag (Cat. No. CDA-HA2H6) and negative control protein respectively, AF488 signal was used to evaluate the binding activity (QC tested).

下载Protocol

Ready-to-use due to validation data with various concentration by flow cytometry

1e5 of Mouse Anti-CD4 antibody coupled beads (5.5 μm) were stained with different concentration of Alexa Fluor™ 647-Labeled Human CD4 Protein, His Tag (Cat. No. CD4-HA2H8) and negative control protein respectively, AF647 signal was used to evaluate the binding activity (QC tested).
 

下载Protocol

高稳定性
高稳定性

Alexa Fluor™ 488-Labeled Human CD7 Protein, His Tag (Cat. No. CD7-HA2H9) is stable at 25℃ for 48 hours, equivalent to store at -70℃ for 2 years and freezing and thawing 3 times without performance reduction.
 

下载Protocol

高批间一致性
高批间一致性

Binding activity of three different lots of Alexa Fluor™ 488-Labeled Human CD7 Protein, His Tag against Anti-CD7 CAR-293 cells was evaluated by flow cytometry. The result shows very high batch-to-batch consistency.

结合活性不受标记影响
结合活性不受标记影响

Immobilized Alexa Fluor™ 647-Labeled Human CD7 Protein, His Tag (Cat. No. CD7-HA2H4) at 1 μg/mL (100 μL/well) can bind Anti-CD7 antibody, Mouse IgG1 with a linear range of 0.05-3 ng/mL (Routinely tested). Labeling with fluorescent dyes did not affect their activity.

下载Protocol

量化的荧光/蛋白质(F/P)比值, 实现抗体密度精准定量

应用案例:验证CD8-LNPs的结合活性与靶向特异性

量化的荧光/蛋白质(F/P)比值, 实现抗体密度精准定量

Alexa Fluor™ 488-Labeled Human CD8 alpha Protein, His Tag (Cat No. CDA-HA2H6) was used to evaluate binding and targeting of CD8-targeted lipid nanoparticles (CD8-LNPs). After, CD8-LNPs were tested to deliver eGFP to immune cells in vitro. Flow cytometry and fluorescence analysis showed high eGFP expression specifically in CD8⁺ cells, confirmed the efficient and selective targeting capability of CD8-LNPs. These results demonstrate the potential of CD8-LNPs for precise delivery of molecular cargo to CD8-expressing cell populations. (Data from Tiva Biosciences).

下载Protocol

CAR阳性率检测工具

资源下载

高品质荧光标记蛋白精准表征In Vivo CAR载体抗体密度

Request PDF
细胞与基因疗法开发解决方案

细胞与基因疗法开发解决方案

Request PDF
CGT关键原料的GMP质量体系深度解读专题

CGT关键原料的GMP质量体系深度解读专题

Request PDF

Star Staining新一代荧光定点标记技术平台及系列产品

Request PDF

生物药质量控制检测解决方案

Request PDF

DNase RNase 活性检测试剂盒

Request PDF
  • 体内CAR-T细胞疗法开发解决方案
  • 递送载体表面抗体密度定量
  • 产品列表
  • 产品优势
  • CAR阳性率检测工具
  • 质量控制相关试剂盒
  • 资源下载